Investigators showed that KDM8’s oncogenic properties in prostate cancer came from its direct interaction with androgen receptor (AR) to affect androgen response and with pyruvate kinase M2 (PKM2) to regulate tumor metabolism. The interaction with AR lead to the elevated expression of androgen response genes in androgen-deprived conditions. [Oncogene]
Full Article

The authors found that an epithelial-mesenchymal transition (EMT)-driving transcription factor Slug was specifically up-regulated under chronic hypoxia and promoted tumor cell migration and invasion. Unexpectedly, processes associated with EMT, such as loss of E-cadherin, were not observed under chronic hypoxia. [Cancer Sci]
Abstract

Investigators showed that bisphenol A and nonylphenol induced apoptosis in prostate and ovary cancer cell lines, in a process dependent on A Disintegrin And Metalloprotease 17 (ADAM17) activation. ADAM17 knockdown completely prevented apoptosis as well as the shedding of ADAM17 substrates. [Int J Mol Sci]
Full Article

Advances in the understanding of the epidemiology, natural history, anatomy, detection, diagnosis, grading, staging, imaging, and management of prostate cancer have changed clinical practice and influenced guideline recommendations. Ongoing research and clinical trials are expected to yield more practice-changing results in the near future. [Nat Rev Urol]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the prostate cell research field.

Under the agreement, Dana-Farber researchers were, and will continue to be, granted permission to conduct independent pre-clinical and clinical studies on select Lilly compounds. All compounds evaluated through this collaboration will continue to be fully owned by Lilly. Financial terms of the agreement were not disclosed. [Eli Lilly and Company]
Press Release

Germany’s largest research organization is funding top-notch science, but it needs to employ more foreign and female researchers — and it is failing to leverage ‘big data’, such as electronic medical records. [Nature News]
Editorial

The European Medicines Agency (EMA) will launch the next phase of its business continuity plan on 1 October 2018 at the latest. This will allow the Agency to safeguard core activities related to the evaluation and supervision of medicines, while it has to intensify its preparations for the physical move to Amsterdam in March 2019 and cope with significant staff loss. [European Medicines Agency]
Press Release

The long wait for a White House science adviser is over. President Donald Trump announced that he intends to nominate meteorologist Kelvin Droegemeier, a university administrator and former vice-chair of the governing board of the U.S. National Science Foundation, to be director of the White House Office of Science and Technology Policy. [ScienceInsider]
Editorial